Stay updated on ARV-471 plus Everolimus in ER+, HER2- Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the ARV-471 plus Everolimus in ER+, HER2- Breast Cancer Clinical Trial page.

Latest updates to the ARV-471 plus Everolimus in ER+, HER2- Breast Cancer Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoChange DetectedThe page has removed detailed information about a Phase 1b study of ARV-471 in combination with everolimus for advanced breast cancer, while adding a new identifier and a revision number.SummaryDifference24%
- Check15 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check22 days agoNo Change Detected
- Check58 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
- Check73 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check80 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
- Check94 days agoChange DetectedThe website has been updated from version v2.14.0 to v2.14.1.SummaryDifference0.1%
Stay in the know with updates to ARV-471 plus Everolimus in ER+, HER2- Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ARV-471 plus Everolimus in ER+, HER2- Breast Cancer Clinical Trial page.